This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives

Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives

Format

Expert Perspective

Time to Complete

1 hour

Released

August 31, 2018

Expires

August 31, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Sponsored by the Academy for Continued Healthcare Learning

Commercial Supporter

This activity is supported by an educational grant from Neurocrine BioSciences.

Program Description

This Clinical Commentary consists of an HD video roundtable discussion with two leading expert psychiatrists in the field, who participate in a panel discussion of tardive dyskinesia (TD) as a widespread and undertreated condition in psychiatric populations, as well as the importance of evidence-based differential diagnostics, newly approved therapeutics for treatment of the condition, and strategies for both personalized and improved patient care. This activity additionally includes an interview with a leading neurologist who reviews diagnostic algorithms for TD and shares her perspective on the impact of new drug approvals and strategies for working together with psychiatrists in managing patients with TD. Throughout the activity, testimonials of a patient with tardive dyskinesia are incorporated to bring relevance to the patient perspective, experience and treatment goals.

Intended Audience

This activity is intended for psychiatrists, neurologists, and other clinicians involved in the management of patients with TD.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate possible clinical indication(s) and patient population(s) that may be at increased risk for tardive dyskinesia (TD)
  • Discuss the role of dopamine antagonists and/or other therapies that may play a role in the pathophysiology of TD
  • Recognize the risks, benefits, and possible complications associated with managing TD in the psychiatric population
  • Describe the importance of differential diagnosis and current evidence-based treatment paradigms for patients at risk for TD
  • Interpret the clinical trial efficacy and safety data of novel and emerging therapies for TD

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

Faculty

Cynthia Comella, MD
Professor, Department of Neurological Sciences
Section of Parkinson’s Disease and Movement Disorders
Rush University Medical Center
Chicago, IL

Dr. Comella discloses the following:
Review Panel: Neurocrine Biosciences

Christoph Correll, MD
Professor, Center for Psychiatric Neuroscience,
The Feinstein Institute for Medical Research
Professor, Psychiatry and Molecular Medicine,
Hofstra Northwell School of Medicine
Medical Director, Recognition and Prevention,
Department of Psychiatry,
The Zucker Hillside Hospital
New York, NY

Dr. Correll discloses the following:
Consultant/Advisor: Alkermes, Allergan, Angelini, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Merck, Neurocrine Biosciences, Otsuka, Pfizer, ROVI, Servier, Sunovion, Takeda, and Teva
Grant Support: Janssen and Teva
Shareholder: LB Pharma
Royalties: UpToDate

John Kane, MD
Professor & Chairman,
Psychiatry, Neurology and Neurosciences
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
Chairman, Department of Psychiatry
The Zucker Hillside Hospital
New York, NY

Dr. Kane discloses the following:
Consultant/Advisor: Alkermes, Allergan, Eli Lilly, Forum, Genentech, Lundbeck, Intracellular Therapies, Merck, Janssen, Johnson & Johnson, Neurocrine Biosciences, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva Pharmaceuticals
Grant Support: Otsuka, Lundbeck, and Janssen
Shareholder: LB Pharma and Vanguard Research Group

Brian, a Tardive Dyskinesia patient for 20+ years
New York, NY

Patient Disclosure: No financial relationships reported

Accredited Provider Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tetrabenazine, Clonazepam and Vitamin E for the management of tardive dyskinesia

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

To obtain credit, a score of 75% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Katlyn Cooper
kcooper@achlcme.org

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue